CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 198 enrolled
Drug / intervention
70 mg SC +4 moredrug
Likely dose
70 mg SCfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00975637
NCT00975637Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Bausch Health Americas, Inc.·interventional·Posted Sep 11, 2009·Updated Jun 26, 2019

In Brief

A Phase 2 clinical trial evaluating 70 mg SC, 210 mg SC, and 3 other interventions for Psoriasis. Completed, enrolled 198 participants.

Detailed Summary

The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 11, 2009
Enrollment StartDec 1, 2009
Primary CompletionJul 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.8 years ago

Interventions

70 mg SCdrug

70 mg SC

210 mg SCdrug

210 mg SC

140 mg SCdrug

140 mg SC

280 mg SCdrug

280 mg SC

Placebodrug

Placebo SC